A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma.

@article{Carvajal2014AP2,
  title={A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma.},
  author={Richard D. Carvajal and Michael K. K. Wong and John A. Thompson and Michael S Gordon and Karl D. Lewis and Anna C Pavlick and Jedd D Wolchok and Patrick B Rojas and Jonathan D Schwartz and Agop Y. Bedikian},
  journal={European journal of cancer},
  year={2014},
  volume={50 12},
  pages={2099-107}
}
BACKGROUND To evaluate the efficacy and safety of ramucirumab (IMC-1121B; LY3009806), a fully human monoclonal antibody targeting the vascular endothelial growth factor receptor-2, alone and in combination with dacarbazine in chemotherapy-naïve patients with metastatic melanoma (MM). METHODS Eligible patients received ramucirumab (10mg/kg) + dacarbazine (1000 mg/m(2)) (Arm A) or ramucirumab only (10mg/kg) (Arm B) every 3 weeks. The primary end-point was progression-free survival (PFS… CONTINUE READING